MedTrace Logo

A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer

NCT00149578 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2007-05-17

No results posted yet for this study

Summary

Induction chemotherapy will be administered every 2 weeks for 6 cycles (about 3 months). Patients who have radiological evidence of progressive disease will be shifted to salvage chemotherapy. Patients who have responsive or stable disease after induction chemotherapy will receive concurrent chemoradiotherapy 3-4 weeks after the last dose of induction chemotherapy. Surgical evaluation will be performed 4-6 weeks after the completion of chemoradiotherapy. Patients who have resectable disease will undergo surgical resection. Postoperative adjuvant chemotherapy with GOFL for 6 cycles will be given for those who have curative resection. Patients who still have unresectable disease or non-curative resection will receive systemic chemotherapy of GOFL till disease progression or unacceptable toxicity.

Conditions

Interventions

DRUG

Gemcitabine Oxaliplatin 5FU and Leucovorin

Sponsors & Collaborators

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • National Taiwan University Hospital

    collaborator OTHER

  • Mackay Memorial Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • National Cheng-Kung University Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Hui-Ju Ch'ang, M.D. · Pancreatic Cancer Disease Committee of Taiwan Cooperative Oncology Group

  • Li-Tzong Chen, Ph.D. · Pancreatic Cancer Disease Committee of Taiwan Cooperative Oncology Group

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-10-31
Completion
2008-10-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00149578 on ClinicalTrials.gov